Cite
HARVARD Citation
Sweeney, C. et al. (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet oncology. 24 (4), pp. 323-334. [Online].